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Aims Myocarditis is a potentially fatal complication of immune checkpoint inhibitors (ICI). Sparse data exist on the use of
cardiovascular magnetic resonance (CMR) in ICI-associated myocarditis. In this study, the CMR characteristics and the
association between CMR features and cardiovascular events among patients with ICI-associated myocarditis are
presented.
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Methods
and results
From an international registry of patients with ICI-associated myocarditis, clinical, CMR, and histopathological findings
were collected. Major adverse cardiovascular events (MACE) were a composite of cardiovascular death, cardiogenic
shock, cardiac arrest, and complete heart block. In 103 patients diagnosed with ICI-associated myocarditis who had a
CMR, the mean left ventricular ejection fraction (LVEF) was 50%, and 61% of patients had an LVEF >_50%. Late gadolin-
ium enhancement (LGE) was present in 48% overall, 55% of the reduced EF, and 43% of the preserved EF cohort.
Elevated T2-weighted short tau inversion recovery (STIR) was present in 28% overall, 30% of the reduced EF, and 26%
of the preserved EF cohort. The presence of LGE increased from 21.6%, when CMR was performed within 4 days of
admission to 72.0% when CMR was performed on Day 4 of admission or later. Fifty-six patients had cardiac pathology.
Late gadolinium enhancement was present in 35% of patients with pathological fibrosis and elevated T2-weighted STIR
signal was present in 26% with a lymphocytic infiltration. Forty-one patients (40%) had MACE over a follow-up time of
5 months. The presence of LGE, LGE pattern, or elevated T2-weighted STIR were not associated with MACE.
...................................................................................................................................................................................................
Conclusion These data suggest caution in reliance on LGE or a qualitative T2-STIR-only approach for the exclusion of ICI-
associated myocarditis.
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Introduction
Harnessing the power of the immune system has revolutionized can-
cer treatment.1,2 Immune checkpoint inhibitors (ICI) are antibodies
that block tumour-driven inhibition of T-cell activation and function
and facilitate an immune-mediated attack on cancer cells. These
therapies are currently approved for a multitude of cancer indications
and the use of ICI is rapidly expanding from late-stage disease to the
first line metastatic and adjuvant settings.3 For context, there are cur-
rently 2004 immuno-modulatory agents against 303 targets, from
864 companies in 3042 active clinical trials.4 Myocarditis is an uncom-
mon toxicity associated with ICI with wide incidence varying from
0.1% to 1%;5,6 however, reporting of ICI-associated myocarditis has
increased, likely due to heightened awareness.7,8 Myocarditis related
to an ICI has a fulminant course, with a case fatality rate of 30–50%.9–
12 Cardiovascular magnetic resonance (CMR), with the use of tissue
characterization techniques such as late gadolinium enhancement
(LGE) and the presence of myocardial oedema, is the gold-standard
non-invasive imaging test for diagnosis and risk prediction in myocar-
ditis of other aetiologies.13–18 Endomyocardial biopsy (EMB) is the
diagnostic gold standard for myocarditis; however, it is underutilized
due to its invasive nature and associated potential complications (rate
0.3–6%).14,19 Beyond case reports and small case series, there are
sparse data characterizing the use of CMR and correlating with EMB
findings in the assessment of ICI-associated myocarditis.20–22 In this
study, the largest cohort of ICI-associated myocarditis was leveraged
to provide the first data on CMR characteristics, to describe the cor-
relation between CMR findings and histopathology, and to test the
association between CMR features and cardiovascular events among
patients with ICI-associated myocarditis.
Methods
Patient cohort
Immune checkpoint inhibitor-associated myocarditis is uncommon, and
to provide insight an international multicentre registry of ICI-associated
myocarditis from 23 sites across the USA, Canada, and Europe
(Supplementary material online, Table S1) was established.10 We included
consecutive patients who were diagnosed with ICI-associated myocardi-
tis by board-certified cardiologists from the participating sites. The first
case in the registry was diagnosed in November 2013, and cases were
included in this report until April 2019. The beginning of follow-up was
the time of first use of ICI. Patients’ clinical characteristics, CMR features,
myocardial biopsy or autopsy data, and outcomes were collected by
investigators at each study site. The study complied with the Declaration
of Helsinki and was approved by each centre’s institutional review com-
mittee; the requirement for written informed consent was waived.
Diagnosis of immune checkpoint inhibitor-
associated myocarditis
Immune checkpoint inhibitor-associated myocarditis was diagnosed in
one of two ways: (i) standard features present on histopathology23 or (ii)
diagnostic criteria for clinically suspected myocarditis based on the
European Society of Cardiology (ESC) guidelines.14 This standardized
diagnostic strategy has been applied to multiple cohorts.24,25
Covariates
Demographics, cardiovascular risk factors, electrocardiograms (ECG),
and echocardiograms were extracted from electronic medical records of
each study site at the time of the index presentation with myocarditis.
Additional covariates included clinical presentation, physical examination,
initial and peak cardiac biomarkers, CMR, EMB, and autopsy results. Initial
troponin and B-type natriuretic peptide (BNP) were defined as the first
measured serum troponin and BNP at the time of admission during the
index hospitalization. Peak troponin and BNP were the maximum meas-
ured troponin and BNP at the index hospitalization. Cancer-specific cova-
riates included the cancer type, ICI treatment, prior cardiotoxic
chemotherapy, and prior radiation.
Cardiovascular magnetic resonance protocol
Patients underwent a CMR at the discretion of the local physicians at the
time of presentation with suspected ICI-associated myocarditis. The
CMR protocol was not protocol-specified and thus reflected local prac-
tice. In summary, all images were acquired with ECG gating, breath-
holding, and the patient in a supine position. Subjects were imaged on
2 L. Zhang et al.
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either a 1.5 or 3 T CMR system. Each CMR protocol included balanced
cine steady-state free precession imaging for cardiac function and mass.
The typical slice thickness was 8 mm with no gap. The protocol also
included black-blood T2-weighted short tau inversion recovery (STIR)
imaging sequences in three short-axis slices and a single long-axis view for
qualitative assessment of myocardial oedema.26 Qualitative T2-weight
STIR signal was evaluated by visual assessment. Where available, the early
gadolinium enhancement ratio was acquired in a free-breathing spin echo
sequence in four identical short-axis slices (basal, mid-basal, mid-apical,
and apical) both before and within the first 3 min after intravenous injec-
tion of contrast. Early gadolinium enhancement was defined as the en-
hancement of myocardium divided by the enhancement of skeletal
muscle in a ratio of >_4.15,18 The presence of LGE was determined 10–
15 min after contrast administration using both magnitude and phase-
sensitive inversion recovery images. Slices were 8 mm thick with 2 mm
gaps. In a subset of patients, T1 measurements and T1 mapping were
available (n= 15). T1 measurements were performed using a Look-
Locker sequence in a single mid-ventricle slice on a 3 T CMR system, pre-
and post-contrast, as previously described.27 T1 mapping sequences
were only performed pre-contrast on a 3 T system using a 5(3)3 MOLLI
in a single mid-ventricle slice. The CMR studies were interpreted at each
site by experienced readers as part of clinical care. The LGE pattern was
categorized as sub-endocardial/transmural, sub-epicardial, mid-myocar-
dial, and diffuse.28 If more than one pattern was present, the predominant
pattern was reported.
Histopathology
Histopathological analysis of cardiac samples obtained by either EMB or
post-mortem autopsy was reported. The performance of histopatho-
logical sampling was not protocol-specified and thus varied per local
practice. It was performed at the time of presentation with myocarditis
(EMB) or with death from a cardiovascular complication with ICI-
associated myocarditis. Typically, at least five biopsies were preferentially
taken from the apical septum of the right ventricle (RV); no left ventricle
(LV) biopsies were performed. The findings were reported by patholo-
gists at each study site according to the 2001 consensus statement from
the Association for European Cardiovascular Pathology.23
Outcomes
The primary outcome of interest, major adverse cardiovascular events
(MACE), was a composite of cardiovascular death, cardiac arrest, cardio-
genic shock, and complete heart block (CHB) requiring a pacemaker. In
case where cardiac arrest, cardiogenic shock, or CHB led to a death, that
case was counted as a cardiac death. When a patient had multiple MACE,
the time of MACE was defined as the date of the earliest event. Standard
definitions were used for cardiovascular death,29 cardiac arrest,30 cardio-
genic shock,31 and CHB. The end of follow-up was on 9 April 2019.
Statistical analysis
Continuous variables were described as mean ± standard deviation or
median (interquartile range) and were compared with the use of
Student’s t-tests or Wilcoxon Rank Sum tests, as appropriate based on
their normality. Normality of continuous variables was tested using the
Shapiro–Wilk test. Categorical variables were presented as percentage
and were compared using the v2 test. The overall agreement and the
Cohen’s kappa coefficient between the site read and a blind reviewer for
LGE and T2-weighted STIR assessment were assessed. Covariates were
compared between patients with and without LGE. Univariable and mul-
tivariable [adjusting for age, sex, number of cardiovascular risk factors,
and lowest left ventricular ejection fraction (LVEF)] Cox proportional
hazards models were performed to examine the association of CMR and
histopathology features with MACE. Harrell’s C-statistics was obtained to
assess the performance of the survival models.32 Sensitivity analysis was
performed by adding study sites in the multivariable-adjusted Cox pro-
portional hazards models. Kaplan–Meier curves for MACE by LGE, myo-
cardial oedema, and pathological fibrosis were presented and compared
with the Logrank test. A two-sided P-value <0.05 was considered signifi-
cant. Analyses were performed with Stata15 (StataCorp, College Station,
TX, USA).
Results
Patient characteristics
All 103 ICI-associated myocarditis patients in the registry through
April 2019 who had a CMR were included. Of these 103 patients, 56
patients were diagnosed with EMB or autopsy and 47 were diagnosed
using the ESC diagnostic criteria for clinically suspected myocarditis
(Supplementary material online, Table S2).14 The mean age was
65.6 ± 15.3 years and 29.1% were female (Table 1). More than half of
the patients presented with shortness of breath. Other common
symptoms included chest pain,33 orthopnoea, paroxysmal nocturnal
dyspnoea, and fatigue (Table 2). At the time of presentation, obstruct-
ive coronary artery disease (CAD) was excluded in 65 patients using
coronary angiography, 16 patients by coronary computed tomog-
raphy angiography, and 16 patients by stress test with imaging (nu-
clear stress test or stress echocardiography). The six patients
without an ischaemia evaluation all had pathology-proven myocardi-
tis (Supplementary material online, Table S2).
Cancer and treatment characteristics
The most common indications for ICI were melanoma and non-
small-cell lung cancer (Table 1). All cases with ICI-associated myocar-
ditis had the ICI permanently discontinued. Most patients (71.8%)
received ICI monotherapy and, among them, 90.5% had anti-
programmed cell death protein 1 therapy (including nivolumab and
pembrolizumab), 8.1% had anti-cytotoxic T-lymphocyte-associated
protein 4 therapy (including ipilimumab and tremelimumab), and
1.4% had anti-programmed death-ligand 1 therapy (including avelu-
mab and atezolizumab). Dual ICI therapy was used in 28.2% of
patients (Table 1).
Cardiovascular magnetic resonance
characteristics
A 1.5 T scanner was used in 81 patients and a 3 T scanner in 22
patients. The mean LVEF, left ventricular end-diastolic volume, and
LV mass index were 49.1%, 147.0 mL and 72.4 g/m2, respectively
(Table 2). A trivial or small pericardial effusion was noted in 19
patients (23.5%) (Table 2). In total, 40 patients (39%) had an LVEF of
<50% and 63 patients (61%) had EF of >_50% (Figure 1A). Late gadolin-
ium enhancement was present in 49 patients (48%) of the entire co-
hort, 43% of cases with a preserved LVEF and 55% of cases with a
reduced EF (Figure 1A). The predominant LGE pattern included sub-
endocardial/transmural (3), sub-epicardial (13), mid-myocardial (24),
and diffuse (9) (Figure 2). In the 14 patients with history of CAD be-
fore starting ICI, including 5 patients with prior myocardial infarction,
4 patients with prior coronary stenting, 6 patients with prior coron-
ary artery bypass grafting (not mutually exclusive), 8 had LGE; with a
CMR in ICI Myocarditis 3
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sub-epicardial pattern in 2 patients, mid-myocardial in 4 patients, and
diffuse pattern in 2 patients. We did not find difference in history of
CAD in patients with (17.4%) or without LGE [12.2%, relative ratio
(RR) 1.4, 95% confidence interval (CI) 0.5–3.8; P= 0.57]. Late gadolin-
ium enhancement was predominantly distributed at the anteroseptal,
inferoseptal, inferior, and inferolateral segments (Supplementary ma-
terial online, Figure S1A). Two of the three patients with sub-
endocardial/transmural pattern had pathology-proven myocarditis.
The third patient had LGE in multiple distributions (apical, apical an-
terior, and apical lateral segments), no obstructive CAD and a clinical
presentation consistent with myocarditis. Qualitative myocardial oe-
dema by T2-weighted STIR was present in 28 patients (28%), in 30%
of the reduced EF and 26% of the preserved EF cohort. Elevated T2-
weighted STIR signal was predominantly distributed at the anterosep-
tal, inferoseptal, and inferior segments (Supplementary material on-
line, Figure S1B). Eighteen patients had both LGE and elevated T2-
weighted STIR signal, 31 patients had LGE and no elevated T2-
weighted STIR signal, 10 patients had elevated T2-weighted STIR sig-
nal and no LGE, and 43 patients had neither elevated T2-weighted
STIR signal or LGE (Figure 1A). Patients with LGE more often had ele-
vated T2-weighted STIR signal (36.7%) than patients without LGE
(18.9%, RR 2.0, 95% CI 1.0–3.9; P= 0.037). In 44 randomly selected
patients, the overall agreement between the site read and a blind re-
viewer was 0.97 for LGE assessment and 0.95 for T2-weighted STIR
assessment. The Cohen’s kappa coefficient was 0.94 for LGE assess-
ment and 0.85 for T2-weighted STIR assessment.
The early gadolinium enhancement ratio was available in a sub-
set of patients and was normal (n= 15, mean 2.8 ± 0.6). Fifteen
patients underwent T1 measurements or T1 mapping. The mean
native T1 value in these 15 patients was 1167.2 ± 32.9 ms, higher
than the normal T1 value at the institution (1100–1150 ms on 3 T;
1000–1100 ms on 1.5 T). The native T1 was similar between
....................................................................................................................................................................................................................
Table 1 Description of immune checkpoint inhibitor-associated myocarditis with and without late gadolinium en-
hancement on cardiovascular magnetic resonance
With CMR (N5 103) LGE present (N5 49) LGE absent (N5 54) P-valuea
Age at start of ICI (years) 65.6 ± 15.3 68.8 ± 10.1 62.8 ± 18.3 0.057
Female 30 (29.1) 13 (26.5) 17 (31.5) 0.67
CV risk factors
Hypertension 56 (55.5) 29 (61.7) 27 (50.0) 0.32
Diabetes mellitus 21 (21.7) 11 (23.9) 10 (19.6) 0.63
No CV risk factors 29 (28.2) 11 (22.5) 18 (33.3) 0.56
Prior coronary artery disease 14 (14.7) 8 (17.4) 6 (12.2) 0.57
Prior stroke 5 (5.3) 3 (6.7) 2 (4.0) 0.67
Prior heart failure 2 (2.1) 1 (2.2) 1 (2.0) 1.00
Chronic kidney disease 5 (6.0) 3 (7.7) 2 (4.4) 0.24
Body mass index (kg/m2) 27.5 ± 6.3 26.6 ± 5.2 28.4 ± 7.2 0.20
Primary cancer type
Head and neck 6 (5.8) 1 (2.0) 5 (9.3) 0.21
Breast 3 (2.9) 3 (6.1) 0 (0) 0.10
Hodgkin’s lymphoma 2 (1.9) 0 (0) 2 (3.7) 0.50
Melanoma 45 (43.7) 17 (34.7) 28 (51.9) 0.11
Non-small-cell lung cancer 15 (14.6) 11 (22.5) 4 (7.4) 0.048
Pancreatic 2 (1.9) 1 (2.0) 1 (1.9) 1.00
Renal cell carcinoma 5 (4.9) 1 (2.0) 4 (7.4) 0.37
Glioblastoma 1 (1.0) 1 (2.0) 0 (0) 0.48
Prior chemotherapy or radiation
Radiation 31 (30.1) 16 (32.7) 15 (27.8) 0.67
Anthracyclines 7 (6.8) 4 (8.2) 3 (5.6) 0.71
ICI regimen
Monotherapy 74 (71.8) 38 (77.6) 36 (66.7) 0.28
Anti-PD1 67 (90.5) 35 (92.1) 32 (88.9) 0.22
Anti-CTLA4 6 (8.1) 2 (5.3) 4 (11.1) 0.68
Anti-PDL1 1 (1.4) 1 (2.6) 0 (0) 0.48
Dual therapy 29 (28.2) 11 (22.5) 18 (33.3) 0.28
Values are mean ± SD or n (%).
Anti-CTLA4, anti-cytotoxic T-lymphocyte-associated protein 4; anti-PD1, anti-programmed cell death protein 1; anti-PDL1, anti-programmed death-ligand 1; CMR, cardiovascu-
lar magnetic resonance; CV, cardiovascular; ICI, immune checkpoint inhibitors; LGE, late gadolinium enhancement; SD, standard deviation.
aComparison between patients with and without LGE using the Student’s t-tests or Wilcoxon Rank Sum tests for continuous variables, as appropriate based on their normality
and the v2 test for categorical variables.
4 L. Zhang et al.
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Table 2 Comparison of clinical presentation and outcomes in patients with and without late gadolinium
enhancement
With CMR
(N5 103)
LGE present
(N549)
LGE absent
(N5 54)
Relative ratio
or difference
(95% CI)a
P-valueb
Time from starting ICI to admission for
myocarditis (days)
64 (33–133) 68 (32–97.5) 74 (29–162) NA 0.44
Myocarditis presentation
Chest pain 29 (28.2) 14 (28.6) 15 (27.8) 1.0 (-0.2 to 0.2) 0.93
Shortness of breath 57 (55.3) 26 (53.1) 31 (57.4) 0.9 (0.7–1.3) 0.66
Orthopnoea 22 (21.8) 9 (19.2) 13 (24.1) 0.7 (0.3–1.4) 0.31
Paroxysmal nocturnal dyspnoea 20 (19.6) 8 (16.7) 12 (22.2) 0.6 (0.3–1.4) 0.26
Fatigue 35 (38.0) 13 (32.5) 22 (42.3) 0.8 (0.5–1.3) 0.31
Syncope 9 (9.6) 5 (11.9) 4 (7.7) 1.7 (0.8–3.8) 0.20
Sudden cardiac death 1 (1.1) 1 (2.4) 0 (0) 2.1 (0.7–6.6) 0.20
Palpitation 26 (25.5) 11 (22.9) 15 (27.8) 0.8 (0.4–1.5) 0.47
Physical exam
Jugular vein distention 30 (29.4) 14 (29.2) 16 (29.6) 1.3 (0.8–2.2) 0.28
Crackles 39 (38.6) 18 (37.5) 21 (39.6) 1.1 (0.7–1.7) 0.84
Lower extremity oedema 35 (34.3) 16 (33.3) 19 (35.2) 1.2 (0.7–1.9) 0.49
SBP (mmHg) 126.6 ± 20.2 124.7 ± 22.8 128.3 ± 17.6 3.6 (-4.9 to 12.0) 0.40
DBP (mmHg) 72.9 ± 11.3 72.3 ± 12.8 73.5 ± 9.7 1.2 (-3.6 to 5.9) 0.62
Electrocardiogram at presentation
Sinus rhythm 82 (80.4) 39 (79.6) 43 (81.1) 1.0 (0.8–1.2) 0.85
ST-segment or T-wave changes 55 (54.5) 25 (53.2) 30 (55.6) 1.0 (0.7–1.4) 0.81
Heart rate (beats/min) 87.0 ± 22.4 87.8 ± 25.1 86.4 ± 20.5 -1.4 (-11.5 to 8.6) 0.78
Biomarkers
Initial troponin T (ng/mL) 0.5 (0.1–1.7) 1.0 (0.2–6.8) 0.4 (0.1–1.1) NA 0.021
Peak troponin T (ng/mL) 1.0 (0.1–2.1) 1.0 (0.2–4.5) 0.9 (0.1–1.9) NA 0.22
Initial BNP (pg/mL) (n= 84) 589 (194–2413) 838 (405–4592) 478.5 (146.5–1350) NA 0.09
Peak BNP (pg/mL) (n= 49) 1088 (242–4873) 1553.5 (734.5–6542.5) 922 (194–2567) NA 0.16
Echocardiogram
Pre-ICI LVEF (%) (n= 66) 61.1 ± 5.7 60.6 ± 5.4 61.6 ± 5.9 1.0 (-1.8 to 3.8) 0.48
Lowest LVEF at presentation (%) 49.8 ± 16.6 47.7 ± 16.3 51.8 ± 16.8 4.2 (-2.3 to 10.7) 0.20
Change of LVEF (%) (n= 66) 12.6±14.3 12.3 ± 12.9 12.9 ± 15.7 0.6 (-7.5 to 7.7) 0.88
LVEF<50% at presentation 40 (38.8) 22 (44.9) 18 (33.3) 0.8 (0.6–1.1) 0.23
LVIDD (mm) 47.8 ± 6.1 48.3 ± 6.1 47.4 ± 6.1 -0.8 (-3.6 to 1.9) 0.53
LVIDS (mm) 35.0 ± 8.8 36.5 ± 8.7 33.5 ± 8.8 -3.0 (-7.3 to 1.4) 0.18
LA size (mm) 38.9 ± 7.6 39.9 ± 8.1 38.1 ± 7.3 -1.8 (-5.8 to 2.2) 0.38
Pericardial effusion 19 (23.5) 8 (22.2) 11 (24.4) 0.9 (0.4–2.0) 0.82
Global longitudinal strain by echo (%) (n= 79) -14.3 ± 2.9 -13.8 ± 3.0 -14.8 ± 2.8 -1.1 (-2.4 to 0.2) 0.099
CMR
1.5 T 81 (78.6) 40 (81.6) 41 (75.9) 0.8 (0.4–1.6) 0.48
3 T 22 (21.4) 9 (18.4) 13 (24.1) 0.8 (0.4–1.6) 0.48
LVEDV (mL) 147.0 ± 39.7 149.1 ± 40.8 145.0 ± 38.9 -4.0 (-19.8 to 11.7) 0.61
LV mass index (g/m2) 72.4 ± 23.9 75.7 ± 26.8 69.3 ± 20.5 -6.4 (-16.0 to 3.1) 0.18
LVEF by CMR (%) 49.1 ± 15.1 47.5 ± 15.9 50.6 ± 14.4 3.1 (-2.8 to 9.0) 0.30
Oedema by T2-weighted STIR 28 (27.5) 18 (36.7) 10 (18.9) 2.0 (1.0–3.9) 0.037
Predominant LGE pattern
Sub-endocardial/transmural NA 3 (6.1) NA NA NA
Sub-epicardial NA 13 (26.5) NA NA NA
Mid-myocardial NA 24 (49.0) NA NA NA
Diffuse NA 9 (18.4) NA NA NA
Native T1 value (ms) (n= 15) 1167.2 ± 32.9 1174.3 ± 34.1 1162.4 ± 33.2 -11.9 (-50.1 to 26.3) 0.51
Extracellular volume (%) (n= 8) 34.3 ± 2.1 34.5 ± 1.9 34.0 ± 2.6 -0.01 (-0.04 to 0.03) 0.77
Early gadolinium enhancement ratio (n= 15) 2.8 ± 0.6 2.8 ± 0.6 2.9 ± 0.6 0.1 (-0.5 to 0.8) 0.72
Continued
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.patients with and without LGE (1174.3 ± 34.1 vs. 1162.4 ± 33.2 ms,
P= 0.51, Table 2). The extracellular volume (ECV) was measured
in eight patients with mean value at 34.3 ± 2.1%, higher than normal
ECV values of 25.3 ± 3.5% in healthy individuals.34 We did not find
difference in ECV between patients with (34.5 ± 1.9%) and without
LGE [34.0 ± 2.6%, difference 0.1% (-0.5% to 0.8%), P= 0.77]
(Table 2).
The demographics, clinical presentation, cancer characteristics,
and outcomes were similar between patients with and without LGE
(Tables 1 and 2), except that patients with LGE were more likely to
have non-small-cell lung cancer (22.5% vs. 7.4%, P= 0.048) and had
higher levels of troponin T on admission (1.0 vs. 0.4 ng/mL,
P= 0.021). The characteristics of patients who did (n= 103) and did
not (n= 39) have a CMR were mostly similar (Supplementary mater-
ial online, Tables S3 and S4). However, the percentage of patients
with prior heart failure, renal cell carcinoma, and the presence of
shortness of breath were higher in patients who did not undergo a
CMR. Diastolic blood pressure and follow-up time were greater in
patients who underwent a CMR. The characteristics of patients diag-
nosed by the ESC criteria (n= 68) and by histopathological criteria
(n= 74) were also compared (Supplementary material online, Tables
S5 and S6).
Histopathology features
Among the 103 patients with a CMR, 56 patients had histopathology
data available, either through EMB (46) or autopsy (10), all of which
were consistent with myocarditis (Figure 1B). In these pathology-
proven patients, analysis reported a lymphocytic infiltration in 55
patients (98%), among whom 21 patients (38%) had LGE and 14
patients (26%) had elevated T2-weighted STIR signal. Thirty-one
patients had pathological fibrosis, among whom 11 patients (35%)
had LGE. A representative case of pathology-proven ICI myocarditis
with normal LGE and normal T2-weighted STIR images is presented
in Supplementary material online, Figure S2. Additionally, two repre-
sentative cases from patients with an autopsy showing diffuse
myocarditis in every segment but with normal LGE and normal
T2-weighted STIR images are presented in Supplementary material
online, Figure S3.
Time from admission to cardiovascular
magnetic resonance
To better understand the CMR findings, the association between
time from onset of myocarditis to CMR and CMR findings was tested.
The time of admission with suspected myocarditis was used as a sur-
rogate of time of symptom onset. Specifically, the time (in days) from
....................................................................................................................................................................................................................
Table 2 Continued
With CMR
(N5 103)
LGE present
(N549)
LGE absent
(N5 54)
Relative ratio
or difference
(95% CI)a
P-valueb
Histopathology (n= 56)
Fibrosis 31 (55.4) 11 (50.0) 20 (58.8) 0.9 (0.5–1.4) 0.52
Lymphocytes (T cell) 55 (98.2) 21 (95.5) 34 (100.0) 1.0 (0.9–1.1) 0.21
Histiocytes 4 (7.1) 1 (4.6) 3 (8.8) 0.5 (0.1–4.6) 0.54
Eosinophils 4 (7.1) 2 (9.1) 2 (5.9) 1.5 (0.2–10.2) 0.65
Outcomes
Follow-up time for MACEc (days) 148.5 (62–304) 136 (63–259) 162 (62–379) NA 0.33
MACE (cumulative incidence)d 41 (39.8) 19 (38.8) 22 (40.7) 1.0 (0.6–1.5) 0.84
MACE (incidence rate, per person-year) 0.63 0.68 0.59 1.2 (0.6–2.2) 0.32
Complete heart block (cumulative incidence) 16 (15.8) 7 (14.6) 9 (17.0) 0.9 (0.3–2.1) 0.74
Complete heart block (incidence rate, per
person-year)
0.25 0.26 0.25 1.0 (0.3–3.1) 0.47
Cardiogenic shock (cumulative incidence) 15 (15.2) 8 (17.0) 7 (13.5) 1.3 (0.5–3.2) 0.62
Cardiogenic shock (incidence rate, per person-year) 0.24 0.29 0.20 1.5 (0.5–4.9) 0.22
Cardiac arrest (cumulative incidence) 15 (15.2) 7 (14.9) 8 (15.4) 0.9 (0.3–2.1) 0.75
Cardiac arrest (incidence rate, per person-year) 0.27 0.26 0.28 0.9 (0.3–2.7) 0.43
CV death (cumulative incidence) 17 (16.5) 6 (12.2) 11 (20.4) 0.6 (0.2–1.5) 0.27
CV death (incidence rate, per person-year) 0.26 0.22 0.30 0.7 (0.2–2.2) 0.28
Values are mean ± SD, n (%), or median (interquartile range).
BNP, B-type natriuretic peptide; CMR, cardiovascular magnetic resonance; CV, cardiovascular; DBP, diastolic blood pressure; ICI, immune checkpoint inhibitors; LA, left atrium;
LGE, late gadolinium enhancement; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVIDD, left ventricular internal diameter end diastole;
LVIDS, left ventricular internal diameter end systole; LV mass, left ventricular mass; MACE, major adverse cardiovascular events; NA, not applicable; SBP, systolic blood pres-
sure; SD, standard deviation; STIR, short tau inversion recovery.
aRelative ratios and 95% CI for categorical variables and difference and 95% CI for normally distributed continuous variables. Cumulative incidence ratio (95% CI) and incidence
rate ratio (95% CI) for MACE and individual MACE categories.
bComparison between patients with and without LGE using the Student’s t-tests or Wilcoxon Rank Sum tests for continuous variables, as appropriate based on their normality
and the v2 test for categorical variables.
cTime of the MACE was defined by the date of the earliest event when multiple MACE happened.
dPatients may have multiple MACE.
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admission to CMR in those with and without LGE was compared.
The time from admission to CMR was longer in patients with LGE
(median time 6 days), compared to patients without LGE (median
time 2 days, P< 0.001) (Table 3). The Locally Weighted Scatterplot
Smoothing method was performed to graphically demonstrate the
relationship between the time from admission to CMR and the pres-
ence of LGE (Figure 3).35 The presence of LGE varied with the time
from admission to CMR. When a CMR was performed on Day 4 of
admission or later, LGE was present in 72.0% of patients. Whereas,
when a CMR was performed within 4 days of admission, LGE was
only present in 21.6% of patients (P< 0.001, Table 3). Performing a
CMR on Day 4 of admission or later was significantly associated with
the presence of LGE (odds ratio 9.35, 95% CI 3.77–23.21; P< 0.001).
The time from admission to CMR was not different in patients with
(median 4 days) or without (median 3 days) elevated T2-weighted
STIR signal (P= 0.88). Those patients with positive pathological fibro-
sis, but negative LGE, had a longer time from admission to biopsy
(median time 11 days), but a shorter time from admission to CMR
(median time 2 days).
Major adverse cardiovascular events
During a median follow-up time of 148.5 days, 41 patients (40%)
developed MACE. The presence of LGE, LGE pattern, elevated T2-
weighted STIR signal on CMR, or pathological fibrosis were not
associated with MACE as their hazard ratios were not statistically sig-
nificant (Table 4), and Kaplan–Meier curves by subgroups overlapped
with each other with a Logrank test P-value >0.05 (Figure 4). In a mul-
tivariable model, a reduced EF was significantly associated with higher
risk of MACE (hazard ratio 2.07, 95% CI 1.10–3.93; P= 0.025)
(Table 4). The results of univariable Cox proportional hazard model
were similar (Table 4). Sensitivity analysis by adding study site as a
covariate did not change the results meaningfully.
Discussion
There are increased reports of myocarditis related to ICI and this ad-
verse effect is fulminant with a mortality rate of 20–50%.6,10 Our
understanding of ICI-associated myocarditis needs to improve as
these revolutionary therapies are being increasingly applied to a
broader range of cancers and to cancers in earlier stages. CMR is the
gold-standard imaging test for the diagnosis of myocarditis, and this
real-world study is the first to describe the use of CMR in the largest
international multicentre cohort of ICI-associated myocarditis. The
study reports the following important and novel findings: (i) more
than half the cases presented with a preserved LVEF; (ii) LGE was
present in less than half of patients with ICI-associated myocarditis
and less among those with a preserved LVEF; (iii) qualitative
Figure 1 Patient cohort of immune checkpoint inhibitor-associated myocarditis. CMR, cardiovascular magnetic resonance; ICI, immune check-
point inhibitors; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; STIR, short tau inversion recovery.
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myocardial oedema by T2-weighted STIR was present in less than
one-third of patients; (iv) varying patterns of LGE were noted includ-
ing sub-endocardial/transmural, sub-epicardial, mid-myocardial, and
diffuse; (v) the time from admission to CMR affected the likelihood of
LGE such as the presence of LGE increased from 21.6% when CMR
was performed within 4 days of admission, to 72.0% when a CMR
was performed on Day 4 of admission or later; (vi) the presence of
LGE or an increase in qualitative T2-weighted STIR signal were not
associated with subsequent MACE; and (vii) the correlation between
LGE and pathological fibrosis and between myocardial oedema by
T2-weighted STIR and lymphocytic infiltration were, at best, modest.
Strengths of the current study include the comparatively large sample
size of patients with ICI-associated myocarditis and the large subset
having both histopathology and CMR data which enabled the unique
opportunity to dissect the relationship between LGE and pathologic-
al fibrosis in ICI-associated myocarditis.
The strengths of CMR for the diagnosis of myocarditis reside in its
excellent spatial resolution and, more importantly, its ability to pro-
vide tissue characterization.13,14,17,36,37,38 Thus, appropriately, CMR is
a primary cardiac imaging modality recommended for the evaluation
of patients with suspected myocarditis.16,17 Beyond research letters
and case reports, there are limited data on the use of CMR for the
diagnosis of ICI-associated myocarditis and no data comparing CMR
to histopathological findings.20 In the current analysis, LGE was pre-
sent in <50% of cases with ICI-associated myocarditis, and 42% of
cases had neither LGE nor an elevated T2-weighted STIR signal. In a
research letter with 15 patients with ICI-associated myocarditis who
underwent a CMR, Escudier et al.20 noted LGE among 23% of
patients and qualitative oedema among 33% of patients. The rate of
LGE and qualitative oedema by T2-weighted STIR is far lower than
that reported for acute myocarditis not related to ICI.16,17,39 For ex-
ample, in a study with 374 patients with acute myocarditis not related
to ICI, LGE was noted in 93% of patients and signs of myocardial oe-
dema by T2-weighted STIR were noted in 94% of patients.17
Similarly, Mahrholdt et al.39 reported that 95% of patients (83/87)
diagnosed with active myocarditis had LGE. An important strength of
our study is the presence of a pathology-proven myocarditis cohort
which noted similar results to the larger cohort. Specifically, 56 of
our patients had both a CMR and histopathological analysis of the
heart and parallel findings were noted where LGE was present in
39% and elevated T2-weighted STIR signal was present in 25% of
patients with pathology-proven myocarditis.
To understand the absence of LGE in patient with myocarditis, fac-
tors associated with LGE were tested. Clinical and imaging parame-
ters were similar in patients with or without LGE. Initial troponin T
levels were higher in patients with LGE, suggesting more myocardial
damage may associate with the presence of LGE on a CMR. The rela-
tionship between the timing of the CMR study and the presence of
LGE was tested. Time of onset of symptoms was not used because,
Figure 2 Representative late gadolinium enhancement pattern.
Representative late gadolinium enhancement images from patients
with immune checkpoint inhibitor-associated myocarditis, showing
a patient with no late gadolinium enhancement (A); a patient with
sub-endocardial/transmural late gadolinium enhancement (B); a pa-
tient with sub-epicardial late gadolinium enhancement (C); a patient
with mid-myocardial late gadolinium enhancement (D); a patient
with diffuse late gadolinium enhancement (E); and a patient with
mixed late gadolinium enhancement (sub-epicardial, mid-myocar-
dial, and transmural) (F). Regions of late gadolinium enhancement
are highlighted using white arrows.
Figure 3 Locally Weighted Scatterplot Smoothing method dem-
onstrating the relationship between the time from admission to car-
diovascular magnetic resonance and the presence of late gadolinium
enhancement. CMR, cardiovascular magnetic resonance; LGE, late
gadolinium enhancement.
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while many patients had new cardiovascular symptoms, some had
vague symptoms. Patients usually had a troponin and/or ECG per-
formed due to these vague symptoms and these abnormal tests trig-
gered the admission. When a CMR was performed on Day 4 of
admission or later, the presence of LGE increased from 21.6% to
72.0%. Myocardial fibrosis/scar, reflected by LGE, is considered a sub-
acute or chronic sequel of myocardial inflammation in myocarditis,
thus it may take some time for myocardial fibrosis to develop and ac-
cumulate before becoming detectable on CMR or biopsy. This finding
of a relationship between onset of myocarditis and the presence of fi-
brosis has also been noted in animal studies of myocarditis.
Specifically, in a murine model of viral myocarditis, myocardial fibrin
deposition first appeared on Day 3 after infection, and myocardial fi-
brosis was not detectable until Day 14 after infection.40 In experi-
mental autoimmune myocarditis rat model, LGE was detected in 3
out of 15 rats at 2 weeks after immunization and LGE was detected in
5 of 8 rats at 5 weeks after immunization.41 However, due to the
retrospective nature of the registry, the timing of CMR was deter-
mined by treating physicians and was likely affected by the severity of
presentation and availability of the test and none of the patients
underwent serial CMR. Thus, these results generated a hypothesis
that the time might affect the presence of LGE in patients with ICI-
associated myocarditis and future prospective studies are warranted
to test this hypothesis. The finding of a limited association between
CMR and histopathology was also consistent among pathology-
proven cases. In the current cohort (and illustrated in the case), CMR
was typically performed early (median time 2 days) and the histopath-
ology was typically performed later (median time 11 days) in patients
with negative LGE and positive histopathological fibrosis. The current
results suggest performing CMR later in the clinical course (>_4 days)
could potentially improve its diagnostic performance. However,
delays in the diagnosis and treatment are not recommended as these
delays are likely to have clinical importance. Specifically, in a prior re-
port of 35 cases, earlier treatment of suspected cases was associated
with a trend towards a lower rate of MACE.10
These findings indicate that, in clinically suspected ICI-associated
myocarditis, the absence of LGE or the absence of increased T2-
weighted STIR signal on a CMR does not exclude the potential diag-
nosis and, until our understanding improves and until future research
offers insights into the role of T1 mapping, T2 mapping, and calcula-
tion of the ECV, an EMB should still be pursued when clinical suspi-
cion remains after a normal CMR. In addition, it is known that T2-
weighted STIR method offers limited sensitivity.42 Late gadolinium
enhancement and T2-weighted STIR imaging are dependent on local
variations in fibrosis or inflammation to become qualitatively appar-
ent. Therefore, CMR techniques sensitive to myocardial inflammation
and oedema, such as T1 mapping, T2 mapping, and calculation of the
.................................................................................................
Table 3 Comparison of time from admission to car-
diovascular magnetic resonance and percentage of
patients with cardiovascular magnetic resonance at dif-
ferent time between patients with and without late
gadolinium enhancement
LGE No LGE P-valuea
Time from admission
to CMR (days)
6 (4–8) 2 (1–5) <0.001
CMR performed >_4 days 72.0% (36/50) 28.0% (14/50) <0.001
CMR performed <4 days 21.6% (11/51) 78.4% (40/51) <0.001
CMR, cardiac magnetic resonance; LGE, late gadolinium enhancement.
aThe time from admission to CMR was compared using the Wilcoxon Rank Sum
tests. The percentage of patients in each time category was compared using the
v2 test.
Figure 4 Kaplan–Meier curves for major adverse cardiovascular
events by late gadolinium enhancement (A), T2-weighted STIR imag-
ing for oedema (B), and pathological fibrosis (C). LGE, late gadolin-
ium enhancement.
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ECV may be instrumental to identify early changes in myocardium be-
fore LGE appears. The native T1 value and ECV of patients with ICI-
associated myocarditis appeared to be higher than normal values
based on a small subset of our patients. Future studies on T1 mapping
and T2 mapping with standard protocol and a large sample size are
warranted.
Histopathology has been reported in a small number of cases with
ICI-associated myocarditis.6,20 In the study by Escudier et al., lympho-
cytic infiltration was found in eight of nine patients. In the current study,
a lymphocytic infiltration was shown in 98% of patients, while fibrosis
was found in 55% of the 56 patients who underwent histopathological
analysis. Subclinical ICI-associated myocarditis cases have also been
reported.22,43 For example, in a case of metastatic melanoma treated
with ipilimumab and nivolumab, cardiac involvement was clinically un-
apparent, but patchy fibrosis and diffuse mononuclear infiltrates of
myocardium were found in post-mortem autopsy.43 Given the poten-
tial of subclinical presentations, the lack of LGE in >50% of patients,
the presence of characteristic histopathological findings with a normal
troponin, it is reasonable to hypothesize that ICI-associated myocardial
injury remains underrecognized and underdiagnosed.44
Outcomes with ICI-associated myocarditis are significantly worse
than myocarditis in broad populations. In this cohort, 40% of patients
Take home ﬁgure Proposal algorithm for diagnosing immune checkpoint inhibitor-associated myocarditis.BNP, B-type natriuretic peptide;
CMR, cardiovascular magnetic resonance; ECG, electrocardiogram; ICI, immune checkpoint inhibitors; LGE, late gadolinium enhancement.
.................................................... ..................................................... .....................................................
....................................................................................................................................................................................................................
Table 4 Univariable and multivariable adjusted analysis of association between cardiovascular magnetic resonance
and histopathological features and major adverse cardiac events
Univariable model Multivariable model 1a Multivariable model 2b
HR (95% CI) P-value C-
statistics
HR (95% CI) P-value C-
statistics
HR (95% CI) P-value C-
statistics
CMR
LGE 1.03 (0.56–1.91) 0.92 0.504 1.16 (0.62–2.18) 0.65 0.550 1.19 (0.63–2.25) 0.58 0.681
Sub-endocardial/transmural 1.95 (0.47–8.04) 0.36 0.506 3.33 (0.78–14.12) 0.10 0.531 3.39 (0.75–15.37) 0.11 0.677
Sub-epicardial 0.72 (0.26–1.99) 0.53 0.514 0.91 (0.32–2.56) 0.86 0.521 1.14 (0.40–3.22) 0.81 0.674
Mid-myocardial 0.54 (0.25–1.19) 0.13 0.529 0.53 (0.24–1.18) 0.12 0.562 0.52 (0.24–1.16) 0.11 0.679
Diffuse 1.80 (0.77–4.20) 0.17 0.514 1.80 (0.77–4.23) 0.18 0.536 1.46 (0.62–3.44) 0.39 0.677
LVEDV, per SD change 1.54 (0.98–2.44) 0.063 0.568 1.25 (0.98–1.59) 0.072 0.588 1.05 (0.79–1.39) 0.74 0.680
LV mass, per SD change 0.82 (0.56–1.20) 0.31 0.540 0.92 (0.63–1.34) 0.67 0.561 0.75 (0.48–1.17) 0.20 0.700
LVEF <50% 2.06 (1.11–3.81) 0.021 0.580 1.84 (0.99–3.44) 0.054 0.574 2.07 (1.10–3.93) 0.025 0.631
Oedema by T2-weighted STIR 1.43 (0.74–2.78) 0.29 0.540 1.38 (0.69–2.74) 0.36 0.568 1.15 (0.57–2.33) 0.69 0.689
Histopathology (n= 56)
Fibrosis 1.41 (0.73–2.72) 0.31 0.557 1.31 (0.66–2.61) 0.45 0.645 1.39 (0.68–2.86) 0.37 0.675
CMR, cardiovascular magnetic resonance; HR, hazard ratio; LGE, late gadolinium enhancement; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection frac-
tion; SD, standard deviation; STIR, short tau inversion recovery.
aMultivariable model 1: Cox proportional hazard model adjusting for age and sex.
bMultivariable model 2: Cox proportional hazard model adjusting for age, sex, number of cardiovascular risk factors, and lowest LVEF by echocardiogram during the index hos-
pitalization. When assessing the association of LVEF by CMR with outcomes, LVEF was removed from the model.
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developed MACE and 16.5% of patients had a cardiovascular death
during a median follow-up time of 5 months. In contrast, among
670 patients admitted to hospital with myocarditis regardless of aeti-
ology, MACE occurred in 15% of patients and death occurred in 4%
of patients during a median follow-up time of 4.7 years.16 This
several-fold increase in MACE in a very short period highlights the ful-
minant nature of ICI-associated myocarditis. However, the predictors
of such a marked increase in adverse outcomes with ICI-associated
myocarditis are not well characterized. In contrast to studies among
patients with non-ICI myocarditis, the presence of LGE was not
found to have prognostic significance.16,17 There are several possible
reasons for this discrepancy. First, LGE was only present in <50% of
patients and, had the CMR been performed later, there would likely
have been more patients with LGE and had an improved statistical
power to assess the association between LGE and outcomes.
Second, the follow-up time was much shorter (5 months) compared
to other studies on prognostic performance of LGE (4–
5 years).16,17,36 Thus, future studies with larger sample size, a longer
follow-up time, should outcomes be improved, and better character-
ization of LGE are warranted.
Limitations
Results of the present study should be interpreted in context. This
was a retrospective study and institutional standards were employed.
CMR protocol was not pre-specified and CMR was read at local sites.
Thus, this study is hypothesis-generating and may have unmeasured
confounding caused by different practice pattern and variation be-
tween readers. Additional CMR sequences such as T1 mapping, T2
mapping, and measurement of the ECV, which have additive value in
non-ICI myocarditis,15,18 and in patients at risk of cardiovascular tox-
icities from cancer therapy,45 were not routinely performed.
However, these results reflect CMR practice in real-life clinical set-
tings and reflect the difficulties in describing an evolving disease.
These findings will reflect the next stage of this iterative process,
where these data have provided the basis for discussions on disease-
specific standardization of imaging and non-imaging protocols. In add-
ition, T2-weight STIR imaging was performed in three short-axis sli-
ces and a single long-axis view, instead of whole short-axis stack.
Endomyocardial biopsy was taken from the apical septum of the RV;
no LV biopsies were performed. However, due to the diffuse inflam-
matory nature of ICI-associated myocarditis as seen in the autopsy
samples, the possibility of missing the diagnosis by RV biopsy less.
While limited, two CMR/autopsy overlaps were provided and there
was pathological myocarditis noted at sites where both the LGE and
the black-blood imaging were normal (Supplementary material on-
line, Figure S3). Some of the early cases may be missed due to atypical
presentation, reliance on LGE-based approaches, and limited aware-
ness. However, as insight has improved over time, we believe that
those included in more recent years are generalizable to the broad
population with ICI-associated myocarditis. The data collection
protocol was standardized but the definitions for such features as
clinical symptoms and physical exam findings (e.g. jugular vein disten-
tion) were not standardized. Therefore, it is important to acknow-
ledge that there is likely variability between investigators and sites
which limited these findings. Finally, the statistical power is likely lim-
ited due to the modest sample size, thus the lack of association
between CMR and EMB features and MACE needs to be tested in fu-
ture studies with a larger sample size.
Conclusions
In this study, the CMR and histopathology features of ICI-associated
myocarditis are presented. LGE is present in >80% of patients with
non-ICI myocarditis; in contrast, LGE is present in <50% of patients
with ICI-associated myocarditis. Increased time between clinical pres-
entation and CMR is associated with greater detection of LGE; how-
ever, delays in diagnosis are not recommended as delayed treatment
in ICI-associated myocarditis may be associated with an increase in
MACE.10 These data suggest caution if using an LGE or qualitative
T2-weighted STIR imaging-only approach to diagnose or exclude ICI-
associated myocarditis, especially among the majority of patients
who have a normal LVEF, and suggest that when there is a clinical sus-
picion of myocarditis, a biopsy be strongly considered in those with a
negative CMR using the sequences applied in this study. Especially
while future studies determine if CMR techniques such as T1 and T2
mapping offer improved diagnostic and prognostic value.
Supplementary material
Supplementary material is available at European Heart Journal online.
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